Trial Profile

A Phase 2a, Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of CBL-514 Injection for the Treatment of Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite (Stage 2)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CBL-514 (Primary)
Indications Cellulite
Focus Therapeutic Use
Acronyms Stage 2
Sponsors Caliway Biopharmaceuticals

Most Recent Events

15 May 2024 Status changed from active, no longer recruiting to completed.
25 Apr 2024 According to a Caliway Biopharmaceuticals media release, company announced topline results: Over 50% of participants demonstrated at least one level of improvement among 4 cellulite severity levels.
25 Apr 2024 Results published in a Caliway Biopharmaceuticals media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com